San Francisco, October 12th, 2017 – Recardio Inc. successfully completes Phase 1 study for Dutogliptin.
San Francisco, Aug. 28th, 2017 – RECARDIO, announced that the European Patent Office (EPA) has issued the notice of allowance for its innovative use patent for the treatment of ischemic diseases.
San Francisco, Jul. 25, 2017 – Recardio is participating in the European Society of Cardiology Congress in Barcelona.
San Francisco, June 21st, 2017 – Recardio Inc. today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the company’s entering the clinical phase 2 development in 2017.
San Francisco, March 27th, 2017 – Recardio Inc. Receives FDA Clearance of IND in Regenerative Therapy Program.